Lung Cancer

Texte du rabat

Care of the lung cancer patient screening, diagnosis, and treatment has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of this fast-changing field, including new screening guidelines, new practice standards, and new treatment advances that have led to higher survival rates. This practical, clinically oriented resource provides thorough, evidence-based coverage from experts in the field, including the increasingly important precision medicine approach in lung cancer planning and management.

• Discusses key topics such as small cell and non-small cell lung cancers; immunotherapy, molecular cohorts including ROS1, BRAF, HER2, Met, and NTRK; oligometastatic disease; and more.

• Covers individualized treatment plans for chemotherapy, radiotherapy, targeted biomarker-derived therapies, and new and emerging immunotherapies.

• Provides excellent visual guidance throughout, including algorithms, pathology specimens, anatomic drawings, and PET/CT and CT imaging for diagnosis and treatment planning.

• Features Top 5 Clinical Pearls” at the beginning of each chapter.

• Shares the experience and knowledge of medical oncologists, radiation oncologists, surgical oncologists, and thoracic radiologists for a real-world tumor board perspective.

• An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.

Contenu

1 Lung Cancer Screening and Prevention
2 Diagnostic Techniques
3 Histology and Molecular Testing
4 SURGICAL CONSIDERATIONS IN LUNG CANCER TREATMENT
5 Surgically Resectable Disease
6 Oligometastatic Disease
7 Locally Advanced Disease
8 First Line Therapy
9 Second line therapy in advanced non-small cell lung cancer (NSCLC)
10 EGFR Mutated Non-Small Cell Lung Cancer: A Clinical Approach
11 Diagnosis and treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer
12 Other Molecular Cohorts including ROS1, BRAF, HER2, Met, NTRK
13 Immunotherapy
14 Small Cell Lung Cancer
Foreword
15 Summary and Looking to the Future